Welcome to our dedicated page for Vivos Therapeutics SEC filings (Ticker: VVOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vivos Therapeutics, Inc. (NASDAQ: VVOS) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a medical technology issuer focused on obstructive sleep apnea (OSA) and related sleep-disordered breathing conditions, Vivos uses its SEC reports to describe its business, device portfolio, acquisitions, financing activities and governance matters.
Through periodic reports such as Forms 10-K and 10-Q, investors can review detailed discussions of Vivos’ operations, including its Complete Airway Repositioning and/or Expansion (CARE) devices, DNA appliance, Vivos Guides, VidaSleep oral appliance and related clinical and commercial initiatives. These filings also explain the company’s strategy of acquiring or affiliating with sleep centers, such as The Sleep Center of Nevada, and its revised OSA provider management model that uses jointly owned management entities.
Current reports on Form 8-K and amendments (8-K/A) highlight specific material events, including the completion of acquisitions, integration updates for sleep centers, clinical data announcements, changes to at-the-market offering programs, and the scheduling or results of stockholder meetings. Proxy statements on Form DEF 14A provide additional detail on board composition, equity incentive plans and matters submitted to stockholders for approval.
On Stock Titan, these VVOS filings are complemented by AI-powered tools that help summarize lengthy documents and highlight key sections, such as risk factor updates, acquisition terms, and descriptions of new management or affiliation agreements. Users can also monitor items like late-filing notifications on Form 12b-25 and other compliance-related submissions. Together, the filings and AI analysis offer a structured view of how Vivos reports its evolving sleep apnea device business and sleep center operations to regulators and investors.
Michael C. Skaff filed an initial Form 3 statement of beneficial ownership for Vivos Therapeutics (VVOS), reporting his position as a 10% owner. The filing details significant holdings through two investment vehicles:
Through V-CO Investors LLC:
- 514,498 shares of common stock
- Pre-Funded Warrant for 2,705,768 shares (exercise price: $0.0001, expires 2034)
- Common Stock Purchase Warrant for 3,220,266 shares (exercise price: $2.204, expires 2029)
Through V-Co Investors 2 LLC:
- 828,000 shares of common stock
- Pre-Funded Warrant for 725,258 shares (exercise price: $0.0001, expires 2035)
- Common Stock Purchase Warrant for 2,329,886 shares (exercise price: $2.23, expires 2030)
Skaff serves as Managing Director of SP Manager LLC, which manages both investment vehicles. He disclaims beneficial ownership except for his pecuniary interest.